Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
1 drugs in development
By Therapeutic Area
top 0
No TA breakdown available.
R&D Momentum
57/100
Pipeline Velocity
19/100
Trial Completion Rate
67/100
Pipeline Concentration
100/100
Pipeline Freshness
39/100
Activity
Last 14 days
Accelerating the Actionability of Treatment in Resected and Locally Advanced Pancreatic Cancer
Canadian Atezolizumab Precision Targeting for Immunotherapy Intervention
Monitoring Physical Function Changes for Patients Living With Pancreatic Ductal Adenocarcinoma: Potential for Better Understanding of Treatment Trajectory and Survival
Pancreatic Cancer Glucose Assessment and Regulation Study
Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis
Earlier
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)